Parp inhibitor inhibits the vasculogenic mimicry through a nf-b-ptx3 axis signaling in breast cancer cells

HIGHLIGHTS

• who: Justine Chivot and collaborators from the Institut Universitaire de Cancu00e9rologie, Sorbonne University, Paris, France have published the paper: PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-B-PTX3 Axis Signaling in Breast Cancer Cells, in the Journal: (JOURNAL)
• what: The authors focus here three PARPis: olaparib (AZD2281), talazoparib PARP inhibitor (PARPi) on the VMonformation of three breast tumor cell lines and an (BMN 673), and veliparib (ABT-888). The authors provide evidence that PARPi could impair the VM formation to inhibit the tumor progression via its action to inhibit the NF-kB activity . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.